Business Wire

OR-GUROBI-OPTIMIZATION

18.8.2020 15:02:14 CEST | Business Wire | Press release

Share
River Logic Selects the Gurobi Optimizer as its Preferred Mathematical Optimization Solver

Gurobi Optimization, LLC and River Logic, Inc today announced that River Logic has chosen the Gurobi Optimizer as the preferred mathematical optimization solver for its prescriptive analytics platform. By embedding the Gurobi Optimizer in its platform, River Logic expects its customers to take full advantage of the capabilities of this best-of-breed solver, leading in many cases to faster solve times and increased profit opportunities.

After a thorough evaluation and selection process, River Logic – which had been using another commercial solver as a component of its prescriptive analytics platform for many years – decided to switch to the Gurobi Optimizer.

River Logic’s Chief Technology Officer Peter Bull said: "We are tremendously excited to announce a long-term partnership with Gurobi to harness the power of their optimization solver technology with River Logic’s unique prescriptive analytics cloud SaaS application. River Logic, now together with Gurobi, is at the forefront of driving prescriptive analytics solutions across an increasing number of industries and organizations, helping them to transform their business operations and capabilities."

There were three main reasons behind River Logic’s decision to switch to the Gurobi Optimizer:

  • Performance : The Gurobi Optimizer is the world’s fastest and most powerful mathematical optimization solver, which is constantly setting new industry standards in terms of speed and solution quality. With the Gurobi Optimizer as a key component of River Logic’s solutions, River Logic customers – many of whom are business users without a background in mathematical programming – will see a substantial reduction in the time it takes to optimally solve complex business problems.
  • Vision : Gurobi’s R&D team – which is comprised of the leading experts in the mathematical optimization software industry – is fully focused on developing and delivering the best mathematical optimization solver technology. This goes hand-in-hand with River Logic’s commitment to providing the best planning and decision-support solutions to its global customers. With Gurobi and River Logic’s commitment to continuous improvement and cutting-edge innovation, River Logic customers can be assured that they are using the state-of-the-art solver – today and in the future.
  • Support : Gurobi’s Support team – which is made up of PhD-level mathematical optimization specialists – is dedicated to providing world-class support for customers using the Gurobi Optimizer. River Logic’s technical team and customers will have access to Gurobi’s Support team – who will be there to assist them and make sure they are able to utilize mathematical optimization as effectively as possible in River Logic’s platform.

Gurobi’s Chief Revenue Officer Duke Perrucci commented: “We are thrilled to have the Gurobi Optimizer power River Logic's suite of first-class optimization applications. Our relentless focus on innovation will allow River Logic's customers to tackle the world's most complex problems at speed and with confidence.”

About Gurobi Optimization

Gurobi produces the world’s fastest and most powerful mathematical optimization solver – the Gurobi Optimizer – which is used by leading global companies across more than 40 different industries to rapidly solve their complex, real-world problems and make automated decisions that optimize their efficiency and profitability.

As the market leader in mathematical optimization software, we aim to deliver not only the best solver, but also the best support – so that companies can fully leverage the power of mathematical optimization (on its own or in combination with other AI techniques such as machine learning) to drive optimal business decisions and outcomes.

Founded in 2008, Gurobi has operations across the USA, Europe, and Asia and has more than 2,500 customers globally including SAP, Air France, Uber, and the National Football League (NFL). For more information, please visit www.gurobi.com or call +1 713 871 9341.

About River Logic

River Logic is on a mission to ensure companies across the globe drive maximum value with every decision, no matter how complex the business problem or how quickly markets shift. As a global innovator in advanced analytics, River Logic offers optimization solutions purpose-built for business users rather than data scientists. Its cloud-based solutions enable enterprise-wide optimization through a revolutionary cloud experience that offers rapid scenario collaboration, data management, workflows, scalability, and more. Companies are finally able to align decisions around complex trade-offs with overarching business objectives without sacrificing speed, agility, and flexibility. For more information, please visit www.riverlogic.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release

–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release

Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release

MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye